Prostate Cancer Diagnostics & Monoclonal Antibody Treatments

Diaprost is at the forefront of developing innovative solutions for prostate cancer diagnosis and treatment through its proprietary monoclonal antibody platform. The company focuses on humanized antibodies that target prostate-specific antigens, particularly Prostate-Specific Antigen (PSA), which is crucial for identifying prostate cancer risk. Their lead project, the hu5A10 antibody, is designed for both therapeutic and diagnostic applications, enabling non-invasive detection and treatment of prostate cancer by delivering radionuclides directly to cancer cells. This dual functionality is enhanced by combining imaging techniques, such as PET and CT/MR, allowing for precise localization of cancerous tissues and effective therapeutic intervention.

In addition to its proprietary technology, Diaprost has established strategic partnerships to further its research and development efforts. Notably, the company has entered into an exclusive licensing agreement with Radiopharm Theranostics for the hu5A10 antibody, which could yield significant financial returns contingent on development milestones. Diaprost's commitment to personalized medicine is underscored by its collaborations with leading cancer research institutions, including Memorial Sloan Kettering Cancer Center, to leverage advanced scientific expertise in molecular medicine, immunology, and oncology. This collaborative approach aims to revolutionize prostate cancer care by providing more reliable diagnostic tools and targeted therapies.

Sweden

Diaprost is a private pharmaceutical research and development company based in Lund, Sweden. The company's principal asset is hu5A10, a novel Theranostic Antibody licensed for development in the treatment and diagnosis of prostate cancer. Diaprost has also announced promising new studies for patients with metastatic prostate cancer, and has entered into license agreements with other companies for the development of its products.

Diaprost

Company Details